Listen to a rapid review of the key hepatology studies from Boston 2016 expected to affect clinical practice, followed by expert answers to participants’ questions.
In this Expert Analysis, Ira M. Jacobson, MD, and Stefan Zeuzem, MD, provide expert interpretation of the most clinically important new data on HCV, HBV, and NASH from this important annual conference.
In this downloadable slideset, expert faculty members Ira M. Jacobson, MD, and Stefan Zeuzem, MD, summarize key studies from this important annual conference.
The 2016 hepatology meeting in Boston offered future solutions to some of my most vexing patient challenges.
The treatment of NASH has challenges not seen in patients with HCV infection, but new trends are emerging.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.